Key Highlights
- Liquidia (NASDAQ:LQDA) rose 50.65% pre-market to a listed USD 26.81 on 182,164 shares, with a market capitalization of USD 2.40 billion and an RSI of 22.5 labeled Down, oversold.
- The company settled all litigation with United Therapeutics on October 13, agreeing to pay USD 380.7 million total, including USD 175 million within 30 business days, resolving six lawsuits including antitrust claims.
- The settlement follows a September 30 ruling that two claims of a United Therapeutics patent were valid and infringed; Liquidia will not appeal and has filed to remove the PH-ILD indication from Yutrepia's label.
- Preliminary third-quarter Yutrepia net product sales were USD 222.7 million, and the stock traded as high as about USD 42 from a USD 26.81 prior close.
What Is Moving the Stock
Liquidia (NASDAQ:LQDA) announced after the close on October 13 a global settlement with United Therapeutics resolving all pending litigation, including six lawsuits and antitrust claims, and securing continued commercialization of Yutrepia for pulmonary arterial hypertension. The company will pay United Therapeutics USD 175 million within 30 business days and USD 145.4 million in two equal installments by January 31 and April 30, 2027, for net payments of USD 380.7 million including USD 60.3 million tied to antitrust claims. The stock closed at USD 26.81, down 3.1%, then jumped 42% to 46% to between about USD 38 and USD 39 in extended and pre-market trading, a five-month high, within a session range of USD 26.13 to USD 42.04.
The Data Behind the Move
The settlement follows a September 30 Delaware ruling that claims 1 and 14 of United Therapeutics' patent were valid and infringed, a ruling that had threatened an injunction on sales. Liquidia agreed not to appeal and submitted a supplement to remove the PH-ILD indication from Yutrepia's label. Preliminary unaudited third-quarter Yutrepia net product sales were USD 222.7 million, so the USD 380.7 million settlement equals about 1.7 times one quarter's sales by simple arithmetic. The USD 2.40 billion market value shown reflects the prior close; at about USD 38.20, equity value is closer to USD 3.4 billion assuming the screen's share count.
Risks and What to Watch
The PH-ILD indication is being removed from the label, the USD 380.7 million in payments will drain cash over time, and the stock has already priced in a large part of the resolution. What to watch next: payment funding, the label change itself, and third-quarter results. This is informational only and not investment advice.
Where Things Stand
Liquidia is moving on a confirmed global settlement that removes a real injunction risk tied to its Yutrepia franchise. A pre-market gain on volume this meaningful can still partially reverse once regular trading opens, so the balance of evidence favors waiting for confirmation before drawing firm conclusions. The next catalysts are payment funding, the label change, and third-quarter results. Verify the latest filings before acting, and treat the figures here as a snapshot.






Please wait processing your request...